Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Moderna reported $1.86 billion in revenue for Q3 2024, a year-over-year increase of 1.7% and a surprise of +47.73% over the Zacks Consensus Estimate of $1.26 billion [1] - The EPS for the same period was $0.03, a significant improvement from -$1.39 a year ago, with an EPS surprise of +101.59% compared to the consensus estimate of -$1.89 [1] Revenue Breakdown - Product sales in the Rest of the World were $324 million, below the average estimate of $362.69 million, representing a year-over-year decline of -56.3% [3] - Product sales in the United States reached $1.22 billion, exceeding the average estimate of $728.42 million, with a year-over-year increase of +33.1% [3] - Net Product sales totaled $1.82 billion, surpassing the eight-analyst average estimate of $1.22 billion, reflecting a year-over-year change of +3.6% [3] - Other revenue was reported at $42 million, significantly higher than the estimated $16.30 million, but showed a year-over-year decline of -43.2% [3] - Grant revenue within Other revenue was $7 million, slightly below the estimated $8.75 million [3] Stock Performance - Over the past month, Moderna's shares have returned -11.5%, contrasting with the Zacks S&P 500 composite's +4.9% change [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [4]